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Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, British Columbia V6T 1Z4, CanadaExperience is a valuable asset in scientiﬁc discovery. It enables the re-
searcher to understandwhat has and has notworked in the past, and the
way that problems can or should be addressed. However sometimes ex-
perience becomes enmired in dogma, and we must become careful as
scientists not to think that what has been done previously is the only
meaningful route forward. A strong object lesson is provided by the an-
tibiotic discovery paradigm. With few exceptions, since the very ﬁrst in-
vestigationswe have considered that the gold standard for discovery of a
useful antibiotic is its ability to kill or prevent the growth of serious bac-
terial pathogens using standard laboratory protocols that have been
enshrined as the Clinical and Laboratory Standards Institute (CLSI)
guidelines (Wiegand et al, 2008). However this single minded faith in a
particular approach has almost certainly favoured the development of
the current antibiotic resistance crisis. The paper of Nizet and colleagues
(Lin et al, 2015) shows clearly that we need to rethink this approach.
We are facing a potentially catastrophic failure of our most valuable
and successful medical asset, antibiotics. A lack of useful antibiotics
would lead to difﬁculties withmajor surgeries, cytotoxic therapy, trans-
plantations, and early-term births, etc, and even minor injuries would
have the potential for serious complications. This is a real concern
since resistance ofmost pathogenic bacteria to essentially all antibiotics,
and especially multiple-antibiotic resistance, is rising steadily, with
rates of almost-untreatable “Superbug” infections reaching proportions
where they seriously impact on outcome in the clinic. Although esti-
mates of deaths from antibiotic-resistant infections are often estimated
to bemoderate (e.g. 23,000 annually in the USA), these estimates fail to
account for the annual 210,000 deaths in the USA from sepsis, which is
triggered by infection and for which antibiotics are the front line (and
clearly often unsuccessful) treatment.
When dealing with bacteria that do not respond to treatment, the
major tactic utilized is antibiotic stewardship, whereby the physician
switches the patient to a new class of antibiotics with different underly-
ing mechanisms of action, and thus mechanisms of resistance. Unfortu-
nately there has been a serious void in the discovery of truly novel
antibiotics and especially of new chemical classes (Singh, 2014). There
are at least three possible reasons for this: (a) conventional antibiotics
are a very hard act to follow since they are inexpensive, often broad in
the spectrum of activity, and tend to be very safe to use— this might ex-
plain the dearth of new discovery despite billions of dollars of invest-
ment in Pharma over the past 20 years; (b) it might be that we have
already exploited all of the available excellent targets, especially given
the requirements for selectivity for bacteria and uptake without efﬂux;DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.05.021.
http://dx.doi.org/10.1016/j.ebiom.2015.07.010
2352-3964/© 2015 The Authors. Published by Elsevier B.V. This is an open access article underand (c) little of antibiotic discovery has been directed to those clear
problem areas in which antibiotics have never proven very successful,
namely sepsis (with an ~30% death rate and 5 million deaths world-
wide), chronic infections especially bioﬁlms (representing 65% of all in-
fections in the clinic and leading to adaptive resistance to essentially all
antibiotics), and infections in individuals, with disturbed immune sys-
tems due to chemotherapy, immunosuppressive disease, or massive in-
juries/burns, who are unable to provide immune support for antibiotic
therapy.
It is clear when viewing the frightening impact of resistance and the
deﬁcit in new discovery that we need to rethink the current discovery
paradigm. In particular, it is important to consider novel, alternative ap-
proaches for creating anti-infectives (e.g. host-directed and immuno-
modulatory treatments, phage-based therapies, anti-virulence
strategies, therapeutic antibodies, and adjustment of the microﬂora by
faecal transplantation or probiotics; Hancock et al., 2012; Nigama et al,
2014). Other “new” approaches include directly addressing the above
described “problem areas” (e.g. antibioﬁlm therapies, correcting host
deﬁcits, treating the immune deﬁcit underlying sepsis; Fuente-Núñez
et al., 2013; Pena et al., 2014), using therapeutic adjuvants that make
antibiotics work better (Gill et al, 2015; Lin et al, 2015), and redeﬁning
the gold standard approach (Lin et al, 2015). The paper of Lin et al in this
issue of EBioMedicine (2015) addresses many of these paradigm-
breaking approaches but, in particular, points to how our thinking
about antibiotics has been muddied by clinging to the old ways.
Lin et al. demonstrate that themost commonly prescribed antibiotic
in the USA, azithromycin, lacks activity when assessed using CLSI
methods vs. the serious MDR Gram negative pathogens Pseudomonas
aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii (three
of the most concerning antibiotic resistance pathogens in our society).
However they reasoned that laboratory medium used for CLSI testing
is quite distinct from the in vivo environment. Thus they tested and
demonstrated excellent bactericidal activity for these pathogens in tis-
sue culture medium that mimics the host environment and is normally
used for growing human cells in culture. Furthermore, although current
clinical guidelines do not recommend the use of azithromycin for the
above organisms, this antibiotic had a clear therapeutic effect in lung
and catheter infection models in mice, increasing survival in one in-
stance by 4 fold to ~90%. Another major observation regarding this an-
tibiotic when evaluated in tissue culture mediumwas the clear synergy
with cationic antimicrobial peptides including the human cathelicidin
LL-37 (whichwas otherwise inactive), and the cationic peptide antibiot-
ic colistin. This indicates the potential for therapeutic adjuvant ap-
proaches in which azithromycin could be administered with an agentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
630 R.E.W. Hancock / EBioMedicine 2 (2015) 629–630to promote penetration into bacteria as well as the potential synergy of
azithromycin with host derived factors (LL-37).
Overall this study provides a powerful argument that we need to
break out of the suffocating limitations of dogma and start to rethink
all aspects of antibiotic discovery ifwe are to stave off an antibiotic resis-
tance crisis.
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